Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the ...

MSD is slashing $3bn (€2.59bn) from its annual spending as it braces for off-brand competition to its Irish-manufactured ...